NCT06690398
Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric Patients
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 10 versions: 10 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 35 → 39 locations
- Notable Eligibility criteria expanded, about 16 words
- Secondary endpoints: details revised at 1 of 1 entry
- Study description expanded, about 3 words
- Minor Site details revised at 2 of 35 sitesv8
- Minor Site details revised at 2 of 35 sitesv7
- Minor Study sites: 34 to 35v6
Show 4 earlier versionsHide 4 earlier versions
- Minor Enrollment target: 174 to 160
- Study sites: 37 to 34
- Primary completion date: Mar 2027 to Jun 21, 2027
- Study completion date: Apr 2027 to Jul 19, 2027
- Minor Study sites: 33 to 37v4
- Minor Start date changed from estimate of Nov 2024 to Nov 22, 2024v3
- Notable Eligibility criteria expanded, about 3 wordsv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Aberrant Behavior Checklist - Irritability (ABC-I)
Timeframe: Week 6
Secondary (1)
Clinical Global Impression-Severity (CGI-S)
Arms and interventions
Lumateperone high doseExperimental
Lumateperone 42 mg for patients ages 13-17 years old
Lumateperone low doseExperimental
Lumateperone 21 mg for patients ages 13-17 years old
PlaceboPlacebo comparator
Placebo
Drugs: Lumateperone high dose, Lumateperone low dose, Placebo
Sites
39 sites in 2 countries
United States 35, Serbia 4